[go: up one dir, main page]

Volpicelli-Daley et al., 2014 - Google Patents

Formation of α-synuclein Lewy neurite–like aggregates in axons impedes the transport of distinct endosomes

Volpicelli-Daley et al., 2014

View HTML @Full View
Document ID
7627303116497552527
Author
Volpicelli-Daley L
Gamble K
Schultheiss C
Riddle D
West A
Lee V
Publication year
Publication venue
Molecular biology of the cell

External Links

Snippet

Aggregates of α-synuclein (α-syn) accumulate in neurons in Parkinson's disease and other synucleinopathies. These inclusions predominantly localize to axons even in the early stages of the disease, but their affect on axon function has remained unknown. Previously …
Continue reading at www.molbiolcell.org (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Similar Documents

Publication Publication Date Title
Volpicelli-Daley et al. Formation of α-synuclein Lewy neurite–like aggregates in axons impedes the transport of distinct endosomes
Wu et al. α-Synuclein (αSyn) preformed fibrils induce endogenous αSyn aggregation, compromise synaptic activity and enhance synapse loss in cultured excitatory hippocampal neurons
Ottolini et al. Alpha-synuclein at the intracellular and the extracellular side: functional and dysfunctional implications
Lindström et al. Extensive uptake of α-synuclein oligomers in astrocytes results in sustained intracellular deposits and mitochondrial damage
Shin et al. Mesenchymal stem cells enhance autophagy and increase β-amyloid clearance in Alzheimer disease models
Dauth et al. Extracellular matrix protein expression is brain region dependent
Marcello et al. Endocytosis of synaptic ADAM10 in neuronal plasticity and Alzheimer’s disease
Groemer et al. Amyloid precursor protein is trafficked and secreted via synaptic vesicles
Florenzano et al. Extracellular truncated tau causes early presynaptic dysfunction associated with Alzheimer’s disease and other tauopathies
Sacino et al. Brain injection of α-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker
Geurts et al. Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis
Yan et al. Spectrin breakdown products (SBDPs) as potential biomarkers for neurodegenerative diseases
Gerdes et al. A nanobody-based fluorescent reporter reveals human α-synuclein in the cell cytosol
Gil et al. Nogo-A expression in the human hippocampus in normal aging and in Alzheimer disease
Langness et al. Cholesterol-lowering drugs reduce APP processing to Aβ by inducing APP dimerization
Myhre et al. Microglia express insulin-like growth factor-1 in the hippocampus of aged APPswe/PS1ΔE9 transgenic mice
Yoshii et al. A Myosin Va mutant mouse with disruptions in glutamate synaptic development and mature plasticity in visual cortex
Seifert et al. Amyloid‐beta induced changes in vesicular transport of BDNF in hippocampal neurons
Scheiblich et al. Microglia rescue neurons from aggregate-induced neuronal dysfunction and death through tunneling nanotubes
Almenar-Queralt et al. UV irradiation accelerates amyloid precursor protein (APP) processing and disrupts APP axonal transport
Follett et al. Retromer's role in endosomal trafficking and impaired function in neurodegenerative diseases
JP2024073445A (en) Methods Related to Parkinson's Disease and Synucleinopathies
Clayton et al. Synaptopathy: presynaptic convergence in frontotemporal dementia and amyotrophic lateral sclerosis
Dewa et al. Neuronal DSCAM regulates the peri-synaptic localization of GLAST in Bergmann glia for functional synapse formation
Arcos et al. IGF2 prevents dopaminergic neuronal loss and decreases intracellular alpha-synuclein accumulation in Parkinson’s disease models